With an increase in its variety of inpatient and outpatient footfall, larger affected person yield, and the continued ramp-up of newly launched services throughout the community, Burjeel Holdings introduced a formidable 128.9 per cent soar in web revenue to AED 148 million (US$40.3 million) within the second quarter of 2025. Web revenue for the primary six months rose 10.6 per cent to AED 187 million (US$50.9 million).
The rise in web revenue for Q2 was additionally as a consequence of a decline in footfall for the month of March, which was attributed by the corporate to the Holy Month of Ramadan.
These numbers have been overwhelmingly reversed within the second quarter of the yr, as inpatient footfall rose 17.7 per cent, and outpatient footfall grew 12 per cent.
Income grew 18.7 per cent to AED 1,403 million (US$382 million) in Q2’25, whereas income for the primary six months rose 12.2 per cent to AED 2,677 million (US$728.9 million). Complete affected person visits reached 3.4 million.
The Group carried out 22,930 surgical procedures, up 18.7 per cent. Mattress occupancy improved to 69 per cent, up from 65 per cent a yr in the past. Inpatient volumes rose 14.6 per cent over the primary half.
The outpatient footfall was pushed by major care and physiotherapy facilities, together with robust demand in oncology, pediatrics, ophthalmology, and household medication. Utilisation improved to 68 per cent, up from 65 per cent in Q1’25.
Oncology remained a core progress driver, with income rising 36.7 per cent in Q2’25 and 38.1 per cent in H1’25. This was made attainable by oncology community enlargement and improved conversion in surgical and superior therapies. Different specialties additionally recorded good positive aspects in H1’25, together with urology (+18 per cent), emergency medication (+17 per cent) and cardiology (+16 per cent).
John Sunil, Chief Government Officer of Burjeel Holdings, commented: “The second quarter delivered exceptionally robust outcomes, with 19 per cent income progress pushed by a 12 per cent improve in affected person footfall and improved yield. EBITDA rose by 59 per cent, accompanied by a margin uplift to 22 per cent. This sturdy efficiency considerably strengthened the first-half final result, underscoring Burjeel Holdings’ resilience and long-term sustainable progress.
“These outcomes replicate tangible progress in key operational areas equivalent to doctor manpower optimisation, formulary administration, and price management, whereas our strategic give attention to super-specialty care is starting to yield measurable advantages, enhancing each income and profitability. We proceed to put money into high-value providers and next-generation care services to help long-term momentum.
“We additionally superior key strategic priorities, reinforcing management in complicated care throughout oncology, transplants, fertility, psychological well being, and diagnostics. Our oncology platform is now the UAE’s largest non-public community, that includes new most cancers clinics and cell and gene remedy capabilities.”
EBITDA rose 59.4 per cent to AED 306 million (US$83.3 million) in Q2’25, fueled by robust income progress, enhanced doctor productiveness, and higher efficiency throughout not too long ago ramped-up property. This contains AED 72 million (US$19.6 million) in positive aspects from lease legal responsibility derecognition following the Dubai Medeor Hospital acquisition. The EBITDA margin expanded 5.6 factors to 21.8 per cent.
In H1’25, EBITDA elevated 14.2 per cent to AED 487 million (US$132.6 million).
“Burjeel Holdings is uniquely positioned to seize vital alternatives throughout the area, supported by rising demand for complicated care and a rising inhabitants. Our focus stays on changing latest investments into sustained enlargement and margin enchancment, whereas sustaining disciplined monetary administration to help long-term shareholder worth,” Sunil added.
“Web revenue progress of 129 per cent within the reporting quarter reinforces this trajectory and strengthens the muse for constant shareholder returns.”
